title: Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma.
abstract: BACKGROUND
  Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment.
  
  
  OBJECTIVE
  To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma.
  
  
  METHODS
  Two years of treatment with an ICS, fluticasone propionate (88 microg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis.
  
  
  RESULTS
  Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications.
  
  
  CONCLUSIONS
  More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.
authors.affiliation: Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, MO 63017, USA. bacharier_L@kids.wustl.edu
authors.forename: Leonard B
authors.initials: LB
authors.lastname: Bacharier
authors.forename: Theresa W
authors.initials: TW
authors.lastname: Guilbert
authors.forename: Robert S
authors.initials: RS
authors.lastname: Zeiger
authors.forename: Robert C
authors.initials: RC
authors.lastname: Strunk
authors.forename: Wayne J
authors.initials: WJ
authors.lastname: Morgan
authors.forename: Robert F
authors.initials: RF
authors.lastname: Lemanske
authors.forename: Mark
authors.initials: M
authors.lastname: Moss
authors.forename: Stanley J
authors.initials: SJ
authors.lastname: Szefler
authors.forename: Marzena
authors.initials: M
authors.lastname: Krawiec
authors.forename: Susan
authors.initials: S
authors.lastname: Boehmer
authors.forename: David
authors.initials: D
authors.lastname: Mauger
authors.forename: Lynn M
authors.initials: LM
authors.lastname: Taussig
authors.forename: Fernando D
authors.initials: FD
authors.lastname: Martinez
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000517:prevention & control*; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D016032:Randomized Controlled Trials as Topic; D012135:Respiratory Sounds / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D000068298:Fluticasone